Biologics for Psoriasis May Also Reduce Coronary Plaque Biologics for Psoriasis May Also Reduce Coronary Plaque
Biologics used as treatment for psoriasis could also help reduce lipid-rich necrotic core, a high-risk plaque associated with cardiovascular events, a prospective, observational study suggests.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 17, 2020 Category: Consumer Health News Tags: Cardiology News Source Type: news

Some Psoriasis Meds May Also Help Prevent Heart Disease
Title: Some Psoriasis Meds May Also Help Prevent Heart DiseaseCategory: Health NewsCreated: 9/15/2020 12:00:00 AMLast Editorial Review: 9/16/2020 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - September 16, 2020 Category: Cardiology Source Type: news

Some Psoriasis Meds May Also Help Prevent Heart Disease
Chronic inflammation in people with psoriasis is associated with the development of plaque in heart arteries, which increases the risk of coronary artery disease. In biologic therapy, patients receive protein-based infusions to reduce inflammation. (Source: WebMD Health)
Source: WebMD Health - September 15, 2020 Category: Consumer Health News Source Type: news

Some Psoriasis Meds May Also Help Prevent Heart Disease
TUESDAY, Sept. 15, 2020 -- Biologic therapy for the skin condition psoriasis may reduce patients'risk of heart disease, new research suggests. Chronic inflammation in people with psoriasis is associated with the development of plaque in heart... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 15, 2020 Category: General Medicine Source Type: news

Lipid-Rich Necrotic Core Linked to Psoriasis Severity
TUESDAY, Sept. 15, 2020 -- For patients with psoriasis, lipid-rich necrotic core (LRNC) is associated with psoriasis severity and cardiovascular risk factors and is reduced for those patients receiving biologic therapy, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 15, 2020 Category: Pharmaceuticals Source Type: news

How to Get Rid of Psoriasis Quickly
Title: How to Get Rid of Psoriasis QuicklyCategory: Diseases and ConditionsCreated: 9/15/2020 12:00:00 AMLast Editorial Review: 9/15/2020 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - September 15, 2020 Category: Dermatology Source Type: news

Biologic therapy for psoriasis may reduce heart disease
(American Heart Association) Biologic therapy for psoriasis - protein-based infusions to suppress inflammation - was associated with a significant reduction in high-risk plaque in heart arteries, over one-year, according to new research.The positive association between biologic therapy and a decrease in high-risk plaque in heart arteries was significant after adjusting for cardiovascular risk factors and psoriasis severity. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 15, 2020 Category: International Medicine & Public Health Source Type: news

Henry ford study finds certain immuno suppressing drugs do not increase risk for COVID-19
(Henry Ford Health System) Patients on immunosuppressive therapy for common skin and rheumatic diseases like psoriasis and rheumatoid arthritis are not at increased risk for contracting COVID-19 and should continue taking their medicine as prescribed, say Henry Ford Health System dermatology researchers in a study published in the Journal of the American Academy of Dermatology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 14, 2020 Category: International Medicine & Public Health Source Type: news

Shift Seen to Newer Agents to Treat Psoriasis
THURSDAY, Sept. 10, 2020 -- Phototherapy use for psoriasis decreased from 2005 to 2018, while use of biologics increased, according to a research letter published online Sept. 4 in Dermatologic Therapy. Mytrang H. Do, Ph.D., from Weill Cornell... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 10, 2020 Category: Pharmaceuticals Source Type: news

The Long Road to a PsA Prevention Trial The Long Road to a PsA Prevention Trial
About one third of all patients with psoriasis will develop psoriatic arthritis in their lifetime. With no definitive blood test for diagnosis, prevention trials are key to identifying high-risk groups.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 5, 2020 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news

Tailoring Treatment for Psoriasis, PsA, and Pregnancy Tailoring Treatment for Psoriasis, PsA, and Pregnancy
Pregnancy drives questions about heritability of the disease in offspring, the impact of the disease on pregnancy outcomes and breastfeeding, and how to best balance risks of treatments.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - September 3, 2020 Category: Dermatology Tags: Dermatology News Source Type: news

Efficacy and Safety of Ixekizumab for Pediatric Psoriasis Efficacy and Safety of Ixekizumab for Pediatric Psoriasis
Is the biologic ixekizumab a safe and effective treatment option for children with moderate-to-severe plaque psoriasis?The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 28, 2020 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Age Alone Should Not Limit Use of Systemic Psoriasis Therapy Age Alone Should Not Limit Use of Systemic Psoriasis Therapy
Patients over age 65 may benefit from systemic psoriasis therapy if clinicians remain aware of comorbidities and concomitant medications, according to a systematic review of data.Reuters Health Information (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - August 27, 2020 Category: Transplant Surgery Tags: Dermatology News Source Type: news

Carotid lumen size linked to death from all causes
Carotid lumen diameter derived from ultrasound scans was linked to a higher...Read more on AuntMinnie.comRelated Reading: Ultrasound shows heart disease risk from psoriasis MRI of carotid artery aids cardiovascular risk assessment Can AI reliably measure carotid intima-media thickness? Can mild carotid atherosclerosis hurt mental cognition? US spots subclinical atherosclerosis in low-risk women (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 21, 2020 Category: Radiology Source Type: news

Characteristics, Symptoms of Psoriasis and Atopic Dermatitis Characteristics, Symptoms of Psoriasis and Atopic Dermatitis
Are psoriasis and atopic dermatitis two distinct and different entities or part of the same disease spectrum?The British Journal of Dermatology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - August 21, 2020 Category: Allergy & Immunology Tags: Dermatology Journal Article Source Type: news

Can Psoriasis Go Away?
Title: Can Psoriasis Go Away?Category: Procedures and TestsCreated: 8/14/2020 12:00:00 AMLast Editorial Review: 8/14/2020 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - August 14, 2020 Category: Dermatology Source Type: news

Beyond PASI 100: Striving for Molecular Clearance Beyond PASI 100: Striving for Molecular Clearance
Andrew Blauvelt, MD, presented a first-of-its-kind study that potentially opens the door to a new, more rigorous standard for treatment success in psoriasis.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - August 12, 2020 Category: Dermatology Tags: Dermatology News Source Type: news

Psoriasis Guidelines Focus on Treatment of Adults Psoriasis Guidelines Focus on Treatment of Adults
The guidelines noted the'key role'of topical corticosteroids in treating psoriasis'especially for localized disease. 'Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - August 10, 2020 Category: Dermatology Tags: Dermatology News Source Type: news

Psoriasis Guidelines Focus on Treatment of Adults
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - August 10, 2020 Category: General Medicine Source Type: news

PCOS Associated With a Two-fold Risk of Developing Psoriasis PCOS Associated With a Two-fold Risk of Developing Psoriasis
PCOS is characterized by androgen elevation that can lead to insulin resistance and metabolic syndrome, which have also been associated with an increased risk of psoriasis.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - August 5, 2020 Category: Dermatology Tags: Ob/Gyn & Women ' s Health News Source Type: news

Inflammation Tied to Thyroid Dysfunction With Psoriasis
FRIDAY, July 31, 2020 -- Thyroid dysfunction in patients with psoriasis may be associated with inflammation caused by psoriasis, according to a study published online June 22 in the Journal of Dermatology. Jianfeng Zheng, from the Tongji University... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 31, 2020 Category: Pharmaceuticals Source Type: news

Monthly News Roundup - July 2020
FDA Approves Wynzora Cream for Adults with Plaque Psoriasis Plaque psoriasis is a chronic skin condition often found on the elbows, knees, scalp and lower back. It is characterized by raised, red lesions with a silvery white scale that may itch,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 31, 2020 Category: Pharmaceuticals Source Type: news

FDA Approves Stelara (ustekinumab) for Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
HORSHAM, Pa., July 30, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson& Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Stelara (ustekinumab) as a treatment... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 30, 2020 Category: Drugs & Pharmacology Source Type: news

Risankizumab, an IL-23p19 Inhibitor for Psoriasis Risankizumab, an IL-23p19 Inhibitor for Psoriasis
This review summarizes the clinical trial results for risankizumab, a biologic that targets IL-23p19, in patients with moderate-to-severe plaque psoriasis.Skin Therapy Letter (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 27, 2020 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Bimekizumab Superior to Cosentyx(R) in Achieving Complete Psoriasis Skin Clearance
The Phase 3b BE RADIANT study met its primary endpoint and all ranked secondary endpoints Bimekizumab demonstrated superiority to Cosentyx® (secukinumab) for PASI 100 at week 16 and PASI 100 at week 48, with no new safety signals observed for bimeki... Biopharmaceuticals, Dermatology UCB, bimekizumab, plaque psoriasis, psoriasis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 24, 2020 Category: Pharmaceuticals Source Type: news

New Potential Advances In Treating Psoriasis: A Skin Condition That Affects 125+ Million People
Although psoriasis has been a well-recognized skin condition for many years, there has been significant progress over the last decade on effective therapeutic models and treatment modalities for this autoimmune condition. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 24, 2020 Category: Pharmaceuticals Authors: Sai Balasubramanian, J.D., Contributor Tags: Healthcare /healthcare Innovation /innovation Business /business Source Type: news

Getting under the skin of psoriasis
(Wyss Institute for Biologically Inspired Engineering at Harvard) Psoriasis afflicts millions of people worldwide, but treatments are limited to small molecules like steroids, which can cause skin thinning and lose their effectiveness over time. A Wyss Institute collaboration has circumvented those problems by using a topical ionic liquid to effectively deliver an RNA-based therapy directly into the skin of mice with psoriasis, which reduced multiple psoriasis-related gene products as well as redness and inflammation, resolving the longstanding challenge of delivering nucleic acids into cells. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 22, 2020 Category: International Medicine & Public Health Source Type: news

FDA Approves Wynzora Cream (calcipotriene and betamethasone dipropionate w/w 0.005%/0.064%) for Adults with Plaque Psoriasis
COPENHAGEN, Denmark, July 22, 2020 / B3C newswire / -- MC2 Therapeutics, a commercial stage pharmaceutical company developing a new standard of topical therapies for chronic inflammatory conditions, announced today that the U.S. Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 22, 2020 Category: Drugs & Pharmacology Source Type: news

FDA Approves Wynzora Cream (calcipotriene and betamethasone dipropionate) for Adults with Plaque Psoriasis
COPENHAGEN, Denmark, July 22, 2020 / B3C newswire / -- MC2 Therapeutics, a commercial stage pharmaceutical company developing a new standard of topical therapies for chronic inflammatory conditions, announced today that the U.S. Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 22, 2020 Category: Drugs & Pharmacology Source Type: news

Lilly's Mirikizumab Superior to Cosentyx(R) (secukinumab) in a Phase 3 Study for Patients with Moderate to Severe Plaque Psoriasis
Mirikizumab met the primary and all key secondary endpoints versus placebo at Week 16 and all key secondary endpoints versus Cosentyx® (secukinumab) at Week 16 and Week 52, including superiority in skin clearance at Week 52 Lilly will submit data fr... Biopharmaceuticals, Dermatology Eli Lilly, mirikizumab, psoriasis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 17, 2020 Category: Pharmaceuticals Source Type: news

Ixekizumab vs. Guselkumab for Moderate-to-severe Psoriasis Ixekizumab vs. Guselkumab for Moderate-to-severe Psoriasis
This study compared early and complete skin clearance in patients with moderate-to-severe plaque psoriasis by the IL-17A inhibitor ixekizumab vs. the IL-23p19 inhibitor guselkumab.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 17, 2020 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Skin Cream May Offer New Psoriasis Treatment Option
The researchers found that among patients randomly assigned to use the cream once a day, roughly one-quarter saw their skin clear up within six weeks (Source: WebMD Health)
Source: WebMD Health - July 16, 2020 Category: Consumer Health News Source Type: news

Johnson & Johnson Reports 2020 Second-Quarter Results
New Brunswick, N.J. (July 16, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2020. “Our second quarter results reflect the impact of COVID-19 and the enduring strength of our Pharmaceutical business, where we saw continued growth even in this environment,” said Alex Gorsky, Chairman and Chief Executive Officer. “Thanks to the tireless work of our colleagues around the world and our broad range of capabilities, we continue to successfully navigate the external landscape, and we remain focused on advancing the development of a vaccine to help address this pandemic...
Source: Johnson and Johnson - July 16, 2020 Category: Pharmaceuticals Source Type: news

New Psoriasis Treatment Option From Skin Cream With Roflumilast
Title: New Psoriasis Treatment Option From Skin Cream With RoflumilastCategory: Health NewsCreated: 7/15/2020 12:00:00 AMLast Editorial Review: 7/16/2020 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - July 16, 2020 Category: Dermatology Source Type: news

Roflumilast Cream Promising for Chronic Plaque Psoriasis
WEDNESDAY, July 15, 2020 -- Roflumilast cream is superior to placebo vehicle cream for reducing psoriasis severity, according to a study published in the July 16 issue of the New England Journal of Medicine. Mark G. Lebwohl, M.D., from the Icahn... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 15, 2020 Category: Pharmaceuticals Source Type: news

FDA Approves Tremfya (Guselkumab) for Psoriatic Arthritis FDA Approves Tremfya (Guselkumab) for Psoriatic Arthritis
Guselkumab, first approved for adults with plaque psoriasis in 2017, has now been approved for adults with active psoriatic arthritis (PsA). The FDA based its approval on two pivotal phase 3 trials.FDA Approvals (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - July 15, 2020 Category: Dermatology Tags: Rheumatology News Source Type: news

Skin Cream Containing Roflumilast May Offer New Treatment Option for Psoriasis
WEDNESDAY, July 15, 2020 -- A cream medication that eases skin inflammation might offer a safer treatment option for people with psoriasis, a new clinical trial suggests. Psoriasis is a chronic skin condition that affects more than 8 million... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 15, 2020 Category: General Medicine Source Type: news

Topical PDE-4 Inhibitor for Psoriasis Effective in Phase 2b Trial Topical PDE-4 Inhibitor for Psoriasis Effective in Phase 2b Trial
Topical roflumilast brought marked improvement in signs and symptoms of chronic plaque psoriasis in a phase 2b trial."Roflumilast cream could really be a game changer," said a trial investigator.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 14, 2020 Category: Consumer Health News Tags: Dermatology News Source Type: news

TREMFYA ® (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis
HORSHAM, PA, July 14, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.[1],[2] TREMFYA is the first treatment approved for active PsA that selectively inhibits interleukin (IL)-23, a naturally occurring cytokine that is involved in normal inflammatory and immune responses associated with the symptoms of PsA. The safety and efficacy of TREMFYA in PsA have b...
Source: Johnson and Johnson - July 14, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Biocon to take on Roche Pharma with its psoriasis drug to treat moderate to severe Covid patients
​​The company is marketing the drug as a replacement to Roche’s tocilizumab (originally approved for rheumatoid arthritis) that is currently in off-label use among Covid-19 patients who suffer from cytokine release syndrome (CRS). (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 14, 2020 Category: Pharmaceuticals Source Type: news

Drug regulator okays psoriasis injection for limited use in treating COVID-19 patients
Considering the unmet medical needs to treat COVID-19, Drugs Controller General of India Dr V G Somani approved monoclonal antibody injection Itolizumab for restricted emergency use for the treatment of 'cytokine' release syndrome in moderate to severe acute respiratory distress syndrome patients due to COVID-19. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 11, 2020 Category: Pharmaceuticals Source Type: news

Sorting Out the Many Mimickers of Psoriasis Sorting Out the Many Mimickers of Psoriasis
' It has an earlier age of onset, usually in infancy, and can occur with the atopic triad that presents with asthma and seasonal allergies as well. 'Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 9, 2020 Category: Consumer Health News Tags: Dermatology News Source Type: news

Eczema symptoms: Whats the difference between eczema and psoriasis?
ECZEMA AND PSORIASIS are skin conditions with similar symptoms, so how do you tell the difference? (Source: Daily Express - Health)
Source: Daily Express - Health - July 2, 2020 Category: Consumer Health News Source Type: news

Happify Health releases new chronic condition management platform, Kopa for Psoriasis
Happify Health, known for its digital mental health programs, today  released a platform targeted towards people with chronic conditions, called Kopa. The first component of this new platform is Kopa for Psoriasis, a product created to provide resources and community for those living with the condition. The company chose to first focus on psoriasis because of the c omorbidities often associated with it, such as stress, depression, anxiety, self-consciousness and impaired social functioning. WHAT’S THE IMPACT? (Source: mobihealthnews)
Source: mobihealthnews - June 29, 2020 Category: Information Technology Source Type: news

SFA Therapeutics Announces FDA Approval To Begin IND Trial
Clinical Trial Examines Human Micro-biome-based Drug SFA002 In Mild to Moderate Plaque Psoriasis PHILADELPHIA, June 29, 2020 -- (Healthcare Sales & Marketing Network) -- SFA Therapeutics, Inc. is pleased to announce that the US FDA has provided approva... Biopharmaceuticals, Dermatology SFA Therapeutics, psoriasis, microbiome (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 29, 2020 Category: Pharmaceuticals Source Type: news

Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosus
SPRING HOUSE, PENNSYLVANIA, June 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today its decision to discontinue the Phase 3 LOTUS study of STELARA® (ustekinumab) in Systemic Lupus Erythematosus (SLE) due to lack of efficacy in SLE.The decision is based on data from a pre-planned interim efficacy analysis. Interim safety findings were consistent with the known safety profile of STELARA, and no new safety signals were identified. Investigators, study participants and health authorities have been informed of the decision. The company intends to thoroughly analyze the totality of...
Source: Johnson and Johnson - June 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Results From Two Phase 3 Trials of Bimekizumab Unveiled Results From Two Phase 3 Trials of Bimekizumab Unveiled
Most patients with moderate to severe psoriasis achieve clearance with the investigational interleukin-17A and IL-17F inhibitor, results from two phase 3 trials show.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 25, 2020 Category: Consumer Health News Tags: Dermatology News Source Type: news

What is the difference between a Cochrane systematic review of interventions and a Cochrane diagnostic test accuracy review?
Cochrane systematic reviews of interventions (intervention reviews) and Cochrane diagnostic test accuracy reviews (DTA reviews) are two types of systematic review.They share the following characteristics:They aim to answer a specific healthcare question to help people make decisions based on up-to-date evidence from research.  They look for all the relevant studies to answer the review question.They appraise the reliability of the studies.They summarize the results to produce a picture of the body of evidence available.  They are systematic because they search for and analyze evidence in a systematic way, accordi...
Source: Cochrane News and Events - June 23, 2020 Category: Information Technology Authors: Rachel Klabunde Source Type: news

How to Prevent and Treat Nail Psoriasis at Home
Title: How to Prevent and Treat Nail Psoriasis at HomeCategory: Health NewsCreated: 6/21/2020 12:00:00 AMLast Editorial Review: 6/22/2020 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - June 22, 2020 Category: Dermatology Source Type: news

How to Prevent and Treat Nail Psoriasis at Home
SUNDAY, June 21, 2020 -- Psoriasis causes painful skin rashes and joints but can also affect the nails, according to the American Academy of Dermatology. Most of the nearly 8 million Americans who suffer from psoriasis will develop nail psoriasis... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 21, 2020 Category: General Medicine Source Type: news